Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
Effect of Inhibitors of the Proton Pump on Intestinal Transporters
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2016-01-25
- Target Recruit Count
- 12
- Registration Number
- NCT02524210
- Locations
- 🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France
To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Zeria Pharmaceutical
- Target Recruit Count
- 54
- Registration Number
- NCT02509923
A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)
- First Posted Date
- 2015-06-22
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Genuine Research Center, Egypt
- Target Recruit Count
- 60
- Registration Number
- NCT02477306
- Locations
- 🇪🇬
Genuine Research Center GRC, Cairo, Egypt
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02475161
To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis
Phase 2
Completed
- Conditions
- Esophagitis, Reflux
- Interventions
- Drug: Z-215 PlaceboDrug: Z-215 20mgDrug: Z-215 10mg
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Zeria Pharmaceutical
- Target Recruit Count
- 503
- Registration Number
- NCT02463643
A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults
Phase 4
Completed
- Conditions
- Gastrointestinal Diseases
- Interventions
- Drug: Idiazole 20mg DR tabs
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT02446483
- Locations
- 🇪🇬
GSK Investigational Site, Cairo, Egypt
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 517
- Registration Number
- NCT02135107
Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02097329
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)
Phase 3
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT02037477
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01990378
- Locations
- 🇮🇳
AXIS Clinicals Limited, Miyapur, Hyderabad, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath